Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Kura Oncology (KURA – Research Report). The associated price target remains the same with $40.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Pantginis has given his Buy rating due to a combination of factors related to Kura Oncology’s promising developments in the treatment of acute myeloid leukemia (AML). The recent results from the KOMET-007 trial, which evaluated the combination of ziftomenib with standard chemotherapy, showed high rates of complete remission and minimal residual disease negativity in patients with specific genetic mutations. These outcomes suggest a strong potential for ziftomenib as an effective first-line treatment option.
Additionally, the safety profile of ziftomenib appears favorable, with manageable side effects comparable to those of standard treatments, and no additional toxicity observed. The anticipation of Phase 3 trials further supports the potential for significant clinical advancements. These promising clinical results and the strategic progression into advanced trials underpin Pantginis’s positive outlook on Kura Oncology’s stock.
According to TipRanks, Pantginis is an analyst with an average return of -20.7% and a 28.00% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Kura Oncology, and Esperion.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $0.00 price target.